Skip to main content


Showing posts from July, 2013

Jobs: Project Manager for Oxford University Chemical Biology Platform

One of our bff's are the guys and gals at the SGC in Oxford, they have recently got a grant to establish a University-wide Chemical Biology Platform, and are now looking for a Project Manager for this effort.

Here are details of the job....

Jobs: diXa Project - Scientific Training & Dissemination Officer (Maternity Cover) at EMBL-EBI

New Drug Approvals 2013 - Pt. XI - Afatinib (GilotrifTM)

ATC code: L01XE13

On July 12th 2013 the FDA approved GilotrifTM (USAN afatinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutation. It is a covalent, irreversible inhibitor of EGFR, ERBB2 and ERBB3.

Non small cell lung cancer (NCLS) (CRUK NCLS; PDQ NCLS) accounts for 78% of lung cancer incidences in the UK and is typically resistant to chemotherapy. In clinical studies, afatinib increased the mean Progression Free Survival to 11.1 months from 6.9 months (compared to standard of care Pemetrexed/Cisplatin). Furthermore, response to treatment was observed in tumors harboring several EGFR mutant species although the duration of response varied from 6.9 months to 16.5 months depending on the mutation .

Afatinib covalently binds to the kinase domains of EGFR (ErbB1, Uniprot: P00533; canSAR: EGFR”), HER2 (ErbB2, Uniprot:P04626; canSAR: ERBB2), and HER4 (ErbB4, Uniprot:Q1530…

USAN Watch: July 2013

The USANs for July 2013 have recently been published.

USAN Research Code InChIKey (Parent)Drug ClassTherapeutic classTargetformofilcon B
n/acontact lens polymerpolymer n/afutuximab992DS, Sym004n/atherapeuticmonoclonal antibodyEGFRmuparfostat, muparfostat sodiumPI-88n/atherapeuticoligosaccharideVEGF, FGF-1, FGF-2omafilcon B

n/acontact lens polymerpolymern/astenfilcon A n/acontact lens polymerpolymern/a